Century Therapeutics, Inc.
3675 Market Street, Suite 200
Philadelphia
PA
19104
United States
Website: https://www.centurytx.com/contact-us/
About Century Therapeutics, Inc.
At Century, we are harnessing the power of adult stem cells to develop best-in-class allogeneic iNK and iT cell therapies for cancer. Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies with significant unmet medical need. To achieve our mission, we are recruiting talented employees with diverse skills and subject matter expertise in order to achieve our scientific and business goals.
Together, we can change the future of cancer care by developing novel curative therapies for patients in need. We are One Century.
Offices in:
• Philadelphia, PA – Corporate Headquarters
• Branchburg, NJ – Our new facility to support the development of novel allogeneic living drugs for oncology treatment
COMPANY MISSION & VALUES
We are “One Century” and we’re on an important journey together to transform the future of cancer treatment. In pursuit of our mission, we firmly adhere to and are driven by our values.
• Integrity
• Passion
• Science
• Courage
CENTURY AT WORK, CENTURY AT PLAY
We believe in balance. We work hard every day to advance innovative immune cell therapies to meet the critical needs of the patients we aim to serve. Our work is driven by revolutionary ideas – not titles – and we value contributions from all. We have assembled a highly productive team that enjoys rigorous innovation and spending time together. If this sounds like an environment in which you would thrive, click the link below to view our current openings.
Stock Exchange: NASDAQ
Stock Symbol: IPSC
CONNECT
Century Therapeutics Inc. is an Equal Employment Opportunity/Affirmative Action Employer - Minority/Female/Disability/Veteran. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, or veteran status or any other characteristic protected by federal, state, or local law. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.
66 articles about Century Therapeutics, Inc.
-
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
12/6/2023
Century Therapeutics today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1.
-
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
12/6/2023
Century Therapeutics today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101.
-
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 10:00 AM ET.
-
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/9/2023
Century Therapeutics, Inc., an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, reported financial results and business highlights for the third quarter ended September 30, 2023.
-
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
11/9/2023
Century Therapeutics, Inc. announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023.
-
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
11/9/2023
Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics, Inc. announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
-
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
11/2/2023
Century Therapeutics, Inc., an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immune-oncology, announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas.
-
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
9/26/2023
Century Therapeutics announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.
-
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
8/9/2023
Century Therapeutics, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2023.
-
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
5/11/2023
Century Therapeutics, Inc., an innovative clinical-stage biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, reported financial results and business highlights for the first quarter ended March 31, 2023.
-
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
4/17/2023
Century Therapeutics announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.
-
Century Therapeutics Announces Leadership Changes
4/12/2023
Century Therapeutics today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023.
-
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
3/16/2023
Century Therapeutics, Inc. today reported financial results and business highlights for the full-year ended December 31, 2022.
-
Century Therapeutics to Present at the AACR Annual Meeting 2023
3/15/2023
Century Therapeutics announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research Annual Meeting on Monday, April 17, 2023.
-
Century Therapeutics to Present at Upcoming Investor Conferences - February 21, 2023
2/21/2023
Century Therapeutics, an innovative clinical-stage biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the management team will participate in the following investor conferences.
-
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
2/8/2023
Century Therapeutics, Inc. announced today that the first patient has been dosed in the first-in-human Phase 1 ELiPSE-1 trial evaluating CNTY-101 in patients with relapsed or refractory CD19 positive B-cell lymphomas.
-
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
1/5/2023
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026.
-
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Century Therapeutics today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT.
-
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Century Therapeutics today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 2:00 PM ET.
-
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
11/11/2022
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced preclinical data from the Company’s iPSC-based cell therapy platform were featured in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.